1832 Asset Management L.P. Makes New $2.95 Million Investment in Qiagen N.V. $QGEN

1832 Asset Management L.P. purchased a new stake in shares of Qiagen N.V. (NYSE:QGEN) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 61,386 shares of the company’s stock, valued at approximately $2,950,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Voya Investment Management LLC raised its position in Qiagen by 52.3% in the first quarter. Voya Investment Management LLC now owns 245,657 shares of the company’s stock valued at $9,845,000 after purchasing an additional 84,332 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Qiagen by 117.0% during the second quarter. JPMorgan Chase & Co. now owns 1,252,948 shares of the company’s stock worth $60,217,000 after buying an additional 675,498 shares during the period. Callan Family Office LLC acquired a new stake in shares of Qiagen in the second quarter valued at $304,000. US Bancorp DE grew its stake in shares of Qiagen by 16.6% in the second quarter. US Bancorp DE now owns 66,901 shares of the company’s stock valued at $3,215,000 after buying an additional 9,544 shares in the last quarter. Finally, Moors & Cabot Inc. raised its holdings in shares of Qiagen by 136.6% in the 2nd quarter. Moors & Cabot Inc. now owns 197,958 shares of the company’s stock valued at $9,514,000 after buying an additional 114,289 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

QGEN stock opened at $47.04 on Friday. The company has a current ratio of 2.60, a quick ratio of 2.30 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $10.46 billion, a P/E ratio of 25.57, a PEG ratio of 2.40 and a beta of 0.68. The business has a 50 day simple moving average of $46.51 and a 200-day simple moving average of $46.97. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $51.88.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The firm had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. During the same period last year, the firm posted $0.57 EPS. Qiagen’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, equities analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Analyst Upgrades and Downgrades

QGEN has been the subject of a number of research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday. Barclays set a $53.00 price target on shares of Qiagen and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Finally, Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Three research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $49.69.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.